Endocannabinoid system and synaptic plasticity: implications for emotional responses.
The endocannabinoid system has been involved in the regulation of anxiety, and proposed as an inhibitory modulator of neuronal, behavioral and adrenocortical responses to stressful stimuli. Brain regions such as the amygdala, hippocampus and cortex, which are directly involved in the regulation of emotional behavior, contain high densities of cannabinoid CB1 receptors. Mutant mice lacking CB1 receptors show anxiogenic and depressive-like behaviors as well as an altered hypothalamus pituitary adrenal axis activity, whereas enhancement of endocannabinoid signaling produces anxiolytic and antidepressant-like effects. Genetic and pharmacological approaches also support an involvement of endocannabinoids in extinction of aversive memories. Thus, the endocannabinoid system appears to play a pivotal role in the regulation of emotional states. Endocannabinoids have emerged as mediators of short- and long-term synaptic plasticity in diverse brain structures. Despite the fact that most of the studies on this field have been performed using in vitro models, endocannabinoid-mediated plasticity might be considered as a plausible candidate underlying some of the diverse physiological functions of the endogenous cannabinoid system, including developmental, affective and cognitive processes. In this paper, we will focus on the functional relevance of endocannabinoid-mediated plasticity within the framework of emotional responses. Alterations of the endocannabinoid system may constitute an important factor in the aetiology of certain neuropsychiatric disorders, and, in turn, enhancers of endocannabinoid signaling could represent a potential therapeutical tool in the treatment of both anxiety and depressive symptoms.
Viveros
María-Paz
MP
Departamento de Fisiología Fisiología Animal II, Facultad de Biología, Universidad Complutense, 28040 Madrid, Spain. pazviver@bio.ucm.es
Marco
Eva-María
EM
Llorente
Ricardo
R
López-Gallardo
Meritxell
M
D000818:Animals; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D004644:Emotions / Q000502:physiology*; D063388:Endocannabinoids; D006801:Humans; D001523:Mental Disorders / Q000503:physiopathology* / Q000523:psychology; D009473:Neuronal Plasticity / Q000502:physiology*; D013569:Synapses / Q000502:physiology*
D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids